Abstract
Tragedies suggest that phase I trials in healthy participants may be highly risky. This possibility raises concern that phase I trials may exploit healthy participants to develop new therapies, making the translation of scientific discoveries ethically worrisome. Yet, few systematic data evaluate this concern. This article systematically reviews the risks of published phase I trials in healthy participants and evaluates trial features associated with increased risks. Data on adverse events and trial characteristics were extracted from all phase I trials published in PubMed, Embase, Cochrane, Scopus, and PsycINFO (1 January 2008-1 October 2012). Inclusion criteria were phase I studies that enrolled healthy participants of any age, provided quantitative adverse event data, and documented the number of participants enrolled. Exclusion criteria included (1) adverse event data not in English, (2) a "challenge" study in which participants were administered a pathogen, and (3) no quantitative information about serious adverse events. Data on the incidence of adverse events, duration of adverse event monitoring, trial agent tested, participant demographics, and trial location were extracted. In 475 trials enrolling 27,185 participants,...Continue Reading
References
Feb 1, 1989·British Journal of Clinical Pharmacology·M OrmeS Hobson
May 1, 1986·British Journal of Clinical Pharmacology·J M Royle, E S Snell
May 1, 1994·British Journal of Clinical Pharmacology·N Baber
May 20, 1998·European Journal of Clinical Pharmacology·M SibilleD V Durand
Oct 20, 2001·Bioethics·Paul McNeill
Feb 9, 2002·Journal of Medical Ethics·J Savulescu, M Spriggs
Apr 16, 2002·The American Journal of Bioethics : AJOB·T Lemmens, C Elliott
Nov 25, 2004·PLoS Medicine·Erick H Turner
Apr 1, 2005·Journal of Medical Ethics·John Harris
May 24, 2005·International Journal of Clinical Pharmacology and Therapeutics·A LutfullinG Wensing
Jul 23, 2005·The American Journal of Bioethics : AJOB·Rosamond Rhodes
May 5, 2006·The New England Journal of Medicine·Robert Steinbrook
May 9, 2006·Nature Biotechnology·Cormac Sheridan
Jun 7, 2006·The American Journal of Bioethics : AJOB·Adil E Shamoo, David B Resnik
Jul 5, 2006·British Journal of Clinical Pharmacology·Michel SibilleEmmanuel Krupka
Oct 19, 2006·Lancet·M J H Kenter, A F Cohen
Apr 6, 2007·Clinical Pharmacology and Therapeutics·N E KassC Flexner
May 18, 2007·JAMA : the Journal of the American Medical Association·Deborah A ZarinDonald A B Lindberg
Oct 5, 2007·The New England Journal of Medicine·Miriam Shuchman
May 30, 2008·The New England Journal of Medicine·Carl Elliott, Roberto Abadie
Dec 11, 2008·PLoS Medicine·Kristin RisingLisa Bero
Feb 20, 2009·PLoS Medicine·Evelyne DecullierFrançois Chapuis
Feb 21, 2009·The New England Journal of Medicine·Alastair J J Wood
Jul 9, 2009·JAMA : the Journal of the American Medical Association·Alec B O'Connor
Nov 11, 2009·PLoS Medicine·Joseph S RossHarlan M Krumholz
Feb 5, 2010·Clinical Pharmacology and Therapeutics·J A DiMasiA Wilson
Mar 2, 2010·Oncology Nursing Forum·Izumi Kohara, Tomoko Inoue
Mar 30, 2010·Journal of Pain & Palliative Care Pharmacotherapy· U S Food And Drug Administration
Aug 4, 2010·Annals of Internal Medicine·Florence T BourgeoisKenneth D Mandl
Aug 20, 2010·Journal of Pain & Palliative Care Pharmacotherapy·UNKNOWN U.S. Food And Drug Administration
Mar 9, 2012·International Braz J Urol : Official Journal of the Brazilian Society of Urology·Kenan Isen
Oct 18, 2012·The American Journal of Bioethics : AJOB·Charles Foster, Aisha Y Malik
Jan 11, 2013·BMJ : British Medical Journal·Iain ChalmersFiona Godlee
Mar 11, 2015·BMJ : British Medical Journal·Amanda HakalaDean Fergusson
Jun 28, 2015·BMJ : British Medical Journal·Ezekiel J EmanuelDavid Wendler
Citations
May 10, 2016·Medicina clínica·Rafael Dal-Ré
Apr 8, 2017·Journal of Clinical Pharmacology·Philip Chaikin
Dec 30, 2017·Clinical Pharmacology and Therapeutics·Joseph DeGeorgeNigel Greene
Apr 26, 2018·AJOB Empirical Bioethics·Lisa McManus, Jill A Fisher
Sep 18, 2018·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Marci D CottinghamJill A Fisher
Oct 10, 2018·Journal of Empirical Research on Human Research Ethics : JERHRE·Jill A FisherRebecca L Walker
Nov 21, 2018·PLoS Medicine·Jill A FisherRebecca L Walker
Feb 6, 2017·Nature·Jonathan Kimmelman, Carole Federico
Jul 13, 2019·The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics·Lisa McManusJill A Fisher
Mar 9, 2019·Current Pharmaceutical Design·Clara YzetJean-Frédéric Colombel
Nov 13, 2019·Journal of Bioethical Inquiry·Jill A FisherRebecca L Walker
May 10, 2020·Journal of Medical Ethics·Euzebiusz Jamrozik, Michael J Selgelid
Dec 5, 2018·Journal of Translational Medicine·Joyson J KarakunnelShivaani Kummar
Feb 13, 2019·Ethics & Human Research·Jill A Fisher, Rebecca L Walker
Aug 17, 2019·The American Journal of Bioethics : AJOB·Erik Malmqvist
Jul 16, 2020·British Journal of Clinical Pharmacology·Maurits F J M VissersGeert Jan Groeneveld
Oct 8, 2020·Expert Review of Clinical Pharmacology·Nan ZhaoYimin Cui
Nov 6, 2020·Clinical Pharmacology and Therapeutics·Ewoud-Jan van HoogdalemMartin Kappler
Feb 6, 2021·The American Journal of Bioethics : AJOB·Holly Fernandez LynchEmily A Largent
Nov 15, 2020·European Journal of Clinical Pharmacology·Zejuan WangJin Wang
Jan 23, 2021·Regulatory Toxicology and Pharmacology : RTP·Paul Baldrick, Andreas Reichl
Feb 2, 2021·Clinical Pharmacology and Therapeutics·Manjunath P Pai
Nov 7, 2020·Journal of Medical Ethics·Ruth Payne
Aug 12, 2021·Clinical and Translational Science·Annemie DeiterenFreya Rasschaert